Roth Capital Affirms Celldex (CLDX) at 'Buy'; Says Growing Varli Profile Continues to be Impressive
Tweet Send to a Friend
Roth Capital affirms Celldex Therapeutics (Nasdaq: CLDX) at Buy with a price target of $7 after the company announced new ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
